Baxter pulls in one stem cell licensee

Baxter International's Biotech Group finally has signed one of its rivals in stem cell separation technology to a non-exclusive license agreement covering patents for the therapeutic uses of anti-CD34 antibodies and stem cell populations.

Applied Immune Sciences Inc. (AISX) will use the antibodies in conjunction with its CELLector stem cell separation device. Baxter holds the exclusive rights to the therapeutic applications under a license from Johns Hopkins and Becton Dickinson and Co. At one time, according to AISX spokesman Jerry Ford, Baxter marketed AISX's research device under an agreement that has since lapsed. Dale Smith, group vice president of Baxter International Inc., sits on AISX's board...